Cardiovascular Event, Coronary Artery Bypass Graft, Diabetes Mellitus
Conditions
Brief summary
Glycosylated Hemoglobin (HbA1c) is considered as one of the best markers to assess the glycaemia treatment over a period of 3 to 4 months, and is considered as predictive marker for perioperative mortality and morbidity. The impact of the elevated HbA1c on the risk of perioperative major cardiovascular events in patients undergoing coronary bypass revascularization (by retrospective analysis of perioperative cardiovascular events and preoperative HbA1c) is evaluated.
Interventions
PROCEDURECoronary Bypass Revascularization
analysis of perioperative major cardiovascular events in diabetic patients
Sponsors
University Hospital, Basel, Switzerland
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* patients with Diabetes mellitus undergoing coronary bypass revascularization since 2012
Exclusion criteria
* disapproval of use of data for research purposes
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| occurence of Major adverse cardiac events | perioperative = in hospital | myocardial infarction, cardiac related death, stroke |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| occurence of severe renal insufficiency | perioperative = in hospital | application of renal replacement therapy (renal dialysis) |
| occurence of sternal wound infection | perioperative = in hospital | sternal wound infection |
| mortality | perioperative = in hospital | death rate perioperative |
Countries
Switzerland
Outcome results
None listed